Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
(Neo)adjuvant erlotinib plus cisplatine verbetert uitkomsten bij stadium III NSCLC
okt 2018 | Longoncologie